Mind The Gap: Different Views Of Success May Drive Large Differences In Estimates Of Pharma Value
Executive Summary
The success rates of late-stage molecules may prove to be higher than current analyst estimates; historical data suggests the biopharma industry has been fairly resilient in its ability to deliver its R&D pipeline while adapting to challenges.
You may also be interested in...
The New Face Of Blockbuster Drugs
Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.